Bioage Labs Inc BIOA

$5.50 -0.45 (-7.56%)

Valuation

Market cap
273,546,000
Revenue TTM
$9,000,000
Net income TTM
$-80,610,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-895.67%
Debt to equity
0.00

Trading

Volume
316,371
Avg volume
779,740
Day's range
$5.45 – $6.02
Shares out
45,897,000
Stochastic %K
75%
Beta
1.19
Analysts
Moderate Buy
Price target
$32.55

Price

Company profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phas...

Show more

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
510 806 1445
Website
https://bioagelabs.com
Address
5885 Hollis Street, Suite 370, EmeryVille, United States

Latest news

Stocktwits

Smitty61 Nov 4, 9:09 AM
$BIOA
0 replies
Rusty_Shackelford2024 Oct 28, 10:30 PM
$BIOA @DougieFreshPicks
0 replies
Mmmmiam Oct 27, 2:00 PM
$BIOA any positive news on the CV trial will send this back to $25. It is a different then the novo drug as it targets receptors are more upstream. Institutional owership accumulation suggests a ton of upside from here. News before end of year on CV then DME next year. This is a potential 5-10x from here and immediate buyout target on good phase 2 results from big pharma. End market for CV is bigger than obesity. Starting a 50k position around $5.
1 replies
BuickRoadmaster Oct 23, 2:24 PM
$BIOA Up to their usual tricks. low volune beatdown. back below 5 again?
1 replies
DougieFreshPicks Oct 21, 11:19 PM
$BIOA $NVO I will check it out thanks!!!
0 replies
Rusty_Shackelford2024 Oct 21, 1:09 PM
$BIOA @DougieFreshPicks look at the reason that this sold off. It had to do with a failed $NVO drug that worked on a different receptor. This company makes a molecule that prevents muscle loss with GLP-1s and is already in phase 2. 3 molecules in the pipeline with a track record of working with bigger pharma players. The largest investment banks have this at a price target between $30 and 70. This is the buy of the century.
1 replies
Rusty_Shackelford2024 Oct 16, 5:56 PM
$BIOA stop loss hunting
0 replies
BuickRoadmaster Oct 16, 4:40 PM
$BIOA another 6% day
1 replies